UNSPSC 51162612: Carbetapentane

This classification denotes a cyclopentane and antitussive agent with the molecular formula C20H31NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 32C726X12W, chemically known as 2-(2-diethylaminoethoxy)ethyl 1-phenylcyclopentane-1-carboxylate; 2-hydroxypropane-1,2,3-tricarboxylic acid but more generally known as pentoxyverine, which bears US NIH Compound Identifier 2562. European Medicines Agency schedules Pentoxyverine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09706MIG.

World Health Organization schedules pentoxyverine in its Anatomical Therapeutic Chemical (ATC) Classification. PENTOXYVERINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: CCN(CC)CCOCCOC(=O)C1(CCCC1)C2=CC=CC=C2.

UNSPSC 51162612 Carbetapentane, a Commodity code, shows minimal relevant recent activity aligned with its nominal scope. The code's name refers to a specific pharmaceutical ingredient, but the two recent state and local opportunities tagged to it involve procurement of finished naloxone products and multi-source generic pharmaceuticals through cooperative purchasing, not carbetapentane as an active pharmaceutical ingredient or bulk pharmaceutical input. The mismatch suggests either miscoding in the source data or that state and local buyers are not currently soliciting carbetapentane directly under this code.

The two opportunities on record involve a county health department (Seminole County, Florida) purchasing finished naloxone and drug deactivation systems, and a multi-state cooperative purchasing vehicle (the Minnesota Multistate Cooperative Purchasing Alliance, administered by the Minnesota Department of Administration) establishing master contracts for generic pharmaceuticals and OTC products to be distributed across state and local facilities in Minnesota and Oregon. Neither opportunity targets carbetapentane as a line item or identifies it as part of the procurement scope. No recent standalone solicitations for carbetapentane or carbetapentane-based formulations appear in the record. Firms pursuing this code should verify tagging accuracy with issuing bodies before investing in bid preparation, as the current activity does not reflect the code's nominal commodity focus.